Publication | Closed Access

Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial

Chemotherapy Versus PlaceboSurgical OncologyGastrointestinal OncologyMedicineGastroenterologyStage Iii GastricSurgeryUpper Gastrointestinal SurgeryOncologyRadiation OncologyGastro-oesophageal Junction Cancer